About the Company
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company's lead drug candidate, repotrectinib, is a next-generation kinase inhibitor targeting the ROS1 and TRK oncogenic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company's pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; TPX-0046, targeting RET, which is being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET; and TPX-0131, a next-generation ALK inhibitor currently pending IND submission. Turning Point's next-generation kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $TPTX News
Turning Point Therapeutics
Bristol Myers Squibb is splashing out $4.1 billion to acquire Turning Point Therapeutics, a clinical-stage biotech whose lead drug is currently in pivotal testing as a treatment for certain lung ...
Bristol Myers to Buy Turning Point Therapeutics in $4.1 Billion Oncology Deal
Bristol Myers will pay $76 per share, in cash, for Turning Point Therapeutics, a 122% premium to the group's Thursday closing price on the Nasdaq, in a deal that has the group's unanimous board ...
Turning Point Brands (NYSE: TPB)
Turning Point Brands, Inc. engages in manufacturing, marketing, and distributing branded consumer products including alternative smoking accessories and consumables with active ingredients.
Turning Point Therapeutics Announces Appointment of Brian Sun, M.S., J.D., as Incoming General Counsel
Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the ...
Turning Point Brands Inc
Advice, rankings and one great story every day.
Omega Therapeutics: 2023 Could Well Be A Turning Point
Among US-listed biotech stocks with promising prospects, investors should consider holding a position in Omega Therapeutics, Inc. as the company calls 2023 a pivotal year. Omega Therapeutics is a ...
Intellia Therapeutics Inc NTLA
We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished ...
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2023 Earnings Call Transcript
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2023 Earnings Call ... RevoMotion and Integrity. We are now turning our focus to ...
DiaMedica Therapeutics Inc.'s (NASDAQ:DMAC) Path To Profitability
With the business potentially at an important milestone, we thought we'd take a closer look at DiaMedica Therapeutics Inc.'s (NASDAQ ... before turning a profit of US$32m in 2026.
Q1 2024 Viking Therapeutics Inc Earnings Call
Brian Lian; President, Chief Executive Officer, Director; Viking Therapeutics Inc Greg Zante; Chief Financial Officer ... increased interest income compared to the same period in 2023. Turning to the ...
TPB Turning Point Brands, Inc.
Turning Point Brands, Inc., together with its subsidiaries, manufactures, markets, and distributes branded consumer products. The company operates through three segments: Zig-Zag Products ...
Turning Point Brands Inc.
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
Loading the latest forecasts...